Phase II proof-of-concept trial of SUVN 502 in patients with cognitive dysfunction.
Phase of Trial: Phase II
Latest Information Update: 19 May 2011
At a glance
- Drugs SUVN 502 (Primary)
- Indications Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders; Parkinson's disease; Schizophrenia
- Focus Therapeutic Use
- Sponsors Suven Life Sciences
- 19 May 2011 Planned initiation date changed from 1 Sep 2009 to 1 Dec 2011.
- 03 Aug 2009 New trial record.